These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 25929767

  • 1. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide.
    Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS.
    Antivir Ther; 2015; 20(8):835-42. PubMed ID: 25929767
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. NTCP-Reconstituted In Vitro HBV Infection System.
    Sun Y, Qi Y, Peng B, Li W.
    Methods Mol Biol; 2017; 1540():1-14. PubMed ID: 27975303
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S.
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S.
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM, Zehnder B, van Westen GJP, Kwakkenbos MJ, IJzerman AP, Oude Elferink RPJ, Beuers U, Urban S, van de Graaf SFJ.
    Sci Rep; 2017 Nov 10; 7(1):15307. PubMed ID: 29127322
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T.
    J Hepatol; 2017 Apr 10; 66(4):685-692. PubMed ID: 27890789
    [Abstract] [Full Text] [Related]

  • 15. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
    Li J, Zong L, Sureau C, Barker L, Wands JR, Tong S.
    J Virol; 2016 Sep 15; 90(18):8302-13. PubMed ID: 27384660
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F, Fardel O, Gripon P.
    Virology; 2015 Jul 15; 481():34-42. PubMed ID: 25765005
    [Abstract] [Full Text] [Related]

  • 17. N-Linked Glycosylation Is Not Essential for Sodium Taurocholate Cotransporting Polypeptide To Mediate Hepatitis B Virus Infection In Vitro.
    Lee J, Zong L, Krotow A, Qin Y, Jia L, Zhang J, Tong S, Li J.
    J Virol; 2018 Aug 01; 92(15):. PubMed ID: 29793953
    [Abstract] [Full Text] [Related]

  • 18. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.
    Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M, Li J, Tong S, Wakita T.
    J Biol Chem; 2015 Feb 27; 290(9):5673-84. PubMed ID: 25550158
    [Abstract] [Full Text] [Related]

  • 19. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
    Blanchet M, Sureau C, Labonté P.
    Antiviral Res; 2014 Jun 27; 106():111-5. PubMed ID: 24717262
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.